Treatment Response Prediction System of Metastatic Colorectal Cancer Based on Circulating Tumor Cells

Fudan University0 sites100 target enrollmentJune 15, 2021

ConditionsColorectal Cancer Stage IV Circulating Tumor Cell

Overview

Phase: N/A
Intervention: Not specified
Conditions: Colorectal Cancer Stage IV
Sponsor: Fudan University
Enrollment: 100
Primary Endpoint: Specificity
Status: Not Yet Recruiting
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

This study enrolling patients with metastatic colorectal cancer. Detecting CTC at different points in the treatment process. Descripting the molecular atlas of CTC in mCRC patients. Building and validating a response prediction system of mCTC patients.

Registry

clinicaltrials.gov

Start Date

June 15, 2021

End Date

December 1, 2025

Last Updated

4 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Fudan University

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Age 18-80 years;
•histologically proven colorectal liver metastasis
•With liver-dominant disease (extrahepatic metastases limited to lung metastases)
•A life expectancy of ≥ 3 months
•Adequate hematologic function: absolute neutrophil count (ANC)≥1.5×109/l, platelets≥75×109/l, and international normalized ratio (INR) ≤1.3
•Adequate liver and renal function: total bilirubin ≤2.0 mg/dl, alanine aminotransferase, aspartate aminotransferase ≤ 5x upper limit of normal, and albumin≥2.5 g/dl, serum creatinine≤2.0 mg/dl
•Written informed consent for participation in the trial.